BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Queensland Health

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: RE36418

« Back to Dashboard

Summary for Patent: RE36418

Title: Contrast media comprising a non-ionic contrast agent with low levels of sodium and calcium ions
Abstract:The physiological acceptability of contrast media, especially media for use in angiography, may be enhanced by inclusion of sub-plasma levels of sodium and calcium and, optionally, potassium and/or magnesium, for example 30 mM Na, 0.15 mM Ca, 0.9 mM K and 0.1 mM Mg.
Inventor(s): Almen; Torsten (Malmo, SE), Baath; Lars (Malmo, SE), Jynge; Per (Trondheim, NO), Oksendal; Audun Nesheim (Oslo, NO)
Assignee: Nycomed Imaging AS (Oslo, NO)
Application Number:08/616,245
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: RE36418

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
90 200580Mar 09, 1990
United Kingdom90 20091Sep 14, 1990

International Patent Family for Patent: RE36418

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria141519► Subscribe
Australia645544► Subscribe
Australia7345191► Subscribe
Canada2076861► Subscribe
China1055864► Subscribe
China1056058► Subscribe
Czechoslovakia9100619► Subscribe
Czech Republic285071► Subscribe
Germany69121562► Subscribe
Denmark0521880► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: